🇺🇸US Compliance

MoCRA Safety Substantiation Requirements: Complete Guide

Understand MoCRA safety substantiation requirements for cosmetics. Learn what adequate substantiation means, required data, and how to document product safety.

Verified January 16, 2026

Guide Information

Published by: Global Cosmetic Regs Editorial Team

Last updated: January 16, 2026

Verified against: 21 USC 364d Safety

Sources: 3 official documents

View our methodology →

This guide is part of our comprehensive MoCRA FDA Guidelines: Complete Compliance Guide for 2026 resource.

What is Safety Substantiation Under MoCRA?

Safety substantiation is the requirement that cosmetic products sold in the United States must have adequate evidence supporting their safety for intended use. Under 21 U.S.C. § 364d, the responsible person for a cosmetic product must ensure and maintain adequate substantiation of safety.

Key Concept

Safety substantiation is not pre-market approval. The FDA does not review or approve safety data before products are sold. However, you must have documentation demonstrating safety that can be provided to FDA upon request or during inspection.

According to FDA's MoCRA guidance, safety substantiation has always been required — cosmetics cannot be "adulterated" — but MoCRA codifies the requirement and strengthens FDA's ability to access safety records.

The statutory requirement for safety substantiation is found in 21 U.S.C. § 364d:

> "The responsible person for a cosmetic product shall ensure, and maintain records supporting, that there is adequate substantiation of safety for such cosmetic product."

This requirement applies to:

  • All cosmetic products sold in the United States
  • Every responsible person (typically the brand owner or manufacturer)
  • Both finished products and individual ingredients

Records Requirement

Under 21 U.S.C. § 364f, safety substantiation records must be maintained and made available to FDA upon request. This is a key enforcement mechanism under MoCRA.

What is "Adequate Substantiation"?

The FDA has not published a formal definition of "adequate substantiation" under MoCRA, but based on FDA safety testing guidance and historical enforcement, adequate substantiation generally includes:

Components of Safety Substantiation

Types of Safety Data
Data TypePurposeWhen Required
Ingredient toxicology dataDemonstrates safety of individual componentsFor all ingredients, especially new or less-studied ones
Finished product testingDemonstrates safety of final formulationRecommended for all products
Stability testingEnsures product remains safe over shelf lifeFor all products with claimed shelf life
Microbiological testingEnsures product is free from harmful microorganismsFor water-containing products and products at risk
Clinical/human testingDemonstrates safety on human skinFor products with novel ingredients or high-risk use
Literature reviewDocuments existing safety knowledgeSupplements other data sources

Acceptable Sources of Safety Data

According to FDA's CIR reference, acceptable safety data sources include:

Acceptable Safety Data Sources

  • Cosmetic Ingredient Review (CIR) safety assessments
  • Published peer-reviewed scientific literature
  • Internal or contracted toxicological testing
  • Supplier certificates of analysis with safety data
  • RIFM (Research Institute for Fragrance Materials) monographs for fragrances
  • IFRA standards and guidelines for fragrance ingredients
  • Historical safe use data
  • Read-across data from structurally similar ingredients

Documentation Requirements

What to Document

Safety substantiation documentation should include:

Building a Safety Substantiation File

1
Complete Ingredient List

Document all ingredients in the formulation with their INCI names, CAS numbers, and concentration ranges. Include all components, even those under 1%.

2
Ingredient Safety Data

For each ingredient, compile toxicological data including acute toxicity, skin irritation/sensitization, eye irritation, genotoxicity (where relevant), and any restrictions or limitations on use.

3
Finished Product Safety Assessment

Document the overall safety evaluation of the finished product considering ingredient interactions, product type, intended use, exposure routes, and target population.

4
Stability Data

Include stability testing results demonstrating the product remains safe and effective throughout its intended shelf life under normal storage conditions.

5
Microbiological Data

For products containing water or at risk of contamination, document challenge testing or preservative efficacy testing results.

6
Supporting Literature

Compile relevant scientific literature, CIR assessments, and other published safety evaluations supporting the safety conclusions.

Record Keeping Requirements

Under 21 U.S.C. § 364f, safety records must be:

Record Keeping Requirements

  • Maintained for the period the product is marketed plus 3 years
  • Available for FDA inspection upon request
  • Kept in English or translated upon request
  • Organized and accessible (no specific format required)
  • Updated when significant new safety information becomes available

No Required Format

Unlike the EU's Cosmetic Product Safety Report (CPSR), MoCRA does not specify a required format for safety substantiation documentation. However, maintaining organized records that can be provided quickly to FDA is strongly recommended.

Testing Requirements

Types of Testing That May Be Needed

Based on FDA guidance, the following testing may be required depending on product type:

Common Safety Tests for Cosmetics
Test TypePurposeWhen Recommended
Human Repeat Insult Patch Test (HRIPT/RIPT)Assesses skin sensitization potential through repeated exposure cyclesProducts with new ingredients, high allergen risk, or leave-on/facial applications
Eye irritation assessmentEvaluates eye safetyEye-area products, products that may contact eyes
Preservative efficacy (challenge test)Confirms adequate preservationWater-containing products
Stability testing (accelerated & real-time)Ensures product stabilityAll products
pH testingConfirms appropriate pH for intended useProducts applied to skin or mucous membranes
Microbial limits testingConfirms product is free from pathogensAll finished products

* Testing requirements vary based on product type, ingredients, and intended use

* Animal testing is not required and is being phased out industry-wide

Alternative Testing Methods

The cosmetics industry has moved away from animal testing. Per FDA guidance, acceptable alternatives include:

  • In vitro testing methods
  • Computational modeling (QSAR)
  • Human volunteer studies (ethically conducted)
  • Read-across from similar ingredients
  • Historical data and literature review

MoCRA vs. EU CPSR Requirements

For brands operating in multiple markets, it's helpful to compare MoCRA safety substantiation with EU requirements:

MoCRA vs. EU Safety Documentation
AspectUS (MoCRA)EU (CPSR)
Required documentNo specific formatCosmetic Product Safety Report (CPSR)
Assessor qualificationNot specifiedQualified Safety Assessor required
FormatFlexible, must be accessibleStandardized two-part format
Pre-market requirementNot reviewed by FDAMust exist before market entry
LanguageEnglish (or translated on request)EU official language of country
Record Retention Requirements
Record TypeUS (MoCRA)EU
Safety substantiation recordsOngoing (no specified end date)10 years after last batch
Adverse event records (standard)6 years10 years (per CPSR)
Adverse event records (small business)3 yearsN/A

Brands Selling in Both Markets

If you already have an EU CPSR for your products, much of that documentation can support your US safety substantiation requirements. However, you may need to add US-specific elements and organize records for FDA accessibility.

Common Mistakes

Avoid These Safety Substantiation Errors

Based on FDA compliance observations and industry experience:

Common Mistakes to Avoid

  • No documentation — relying solely on 'the product has been sold safely for years'
  • Incomplete ingredient data — missing toxicological information for some ingredients
  • Outdated information — not updating records when new safety concerns emerge
  • Poor organization — unable to locate records quickly during inspection
  • Relying only on supplier data — not verifying supplier safety claims
  • Ignoring CIR restrictions — using ingredients above CIR recommended limits
  • No stability data — cannot demonstrate product remains safe over shelf life
  • Missing micro testing — for water-containing products requiring preservation

Working with the Cosmetic Ingredient Review (CIR)

The Cosmetic Ingredient Review (CIR) is an industry-funded panel that evaluates ingredient safety. CIR assessments are valuable for safety substantiation because:

  • CIR reviews are recognized by FDA
  • Reviews are publicly available at cir-safety.org
  • Conclusions include safe use conditions and concentrations
  • Regular updates as new data becomes available

Using CIR Data

When using CIR assessments for safety substantiation, verify your ingredient concentrations and use conditions comply with CIR conclusions. Document any deviations and provide additional safety data to support them.

Fragrance Safety: RIFM and IFRA

For fragrance ingredients, additional safety resources include:

  • RIFM (Research Institute for Fragrance Materials): Maintains safety data on fragrance materials, per RIFM
  • IFRA Standards: IFRA publishes standards limiting fragrance ingredient use based on safety data

Compliance with IFRA standards provides strong evidence of fragrance safety.

Good Manufacturing Practices (GMP)

While not strictly "safety substantiation," following ISO 22716 Good Manufacturing Practices supports product safety by ensuring:

  • Consistent, controlled manufacturing processes
  • Proper ingredient handling and storage
  • Contamination prevention
  • Quality control testing
  • Traceability of ingredients and products

FDA's GMP draft guidance recommends following ISO 22716 or equivalent standards.

Safety substantiation is required under 21 U.S.C. § 364d for all cosmetics
No specific format required, but records must be maintained and accessible to FDA
Document ingredient toxicology, finished product safety, stability, and micro testing
CIR assessments are valuable and FDA-recognized safety data sources
Records must be kept for market period plus 3 years
EU CPSR documentation can support US requirements but may need adaptation

Need Help with Safety Documentation?

Our regulatory specialists can help you build a comprehensive safety substantiation file that meets MoCRA requirements.

Get Expert Help

Frequently Asked Questions

Sources & References
  1. U.S. Food and Drug Administration. "Modernization of Cosmetics Regulation Act of 2022 (MoCRA) Overview." (2023-12). fda.gov. Accessed 2026-01-12.
  2. U.S. Food and Drug Administration. "Product Testing of Cosmetics (Safety Substantiation)." (2022-11). fda.gov. Accessed 2026-01-12.
  3. U.S. House of Representatives. "21 U.S.C. § 364d - Safety Substantiation (MoCRA)." (2025-01). uscode.house.gov. Accessed 2026-01-12.